依折麦布联合瑞舒伐他汀对冠心病血脂、颈动脉粥样硬化斑块和超敏C反应蛋白的影响

目的 探讨依折麦布联合瑞舒伐他汀对冠心病患者血脂、颈动脉粥样硬化斑块和超敏C反应蛋白(hs-CRP)的影响.方法 选择青岛大学附属中心医院2015年1月—2016年8月收治的冠心病102例,根据治疗方式分为观察组和对照组,每组51例.对照组采用单纯瑞舒伐他汀治疗,观察组在对照组基础上采用依折麦布治疗.比较2组治疗前后血脂、颈动脉粥样硬化斑块和hs-CRP变化及不良反应情况.结果 2组治疗1、3个月后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及观察组甘油三酯(TG)均较治疗前降低,且观察组低于对照组(P<0.05).2组治疗后颈动脉粥样硬化斑块和hs-CRP水平均较治疗前降低,且观察组低于对照组(P<0.05).2组不良反应总发生率比较差异无统计学意义(P>0.05).结论 依折麦布联合瑞舒伐他汀治疗冠心病可有效改善患者血脂、颈动脉粥样硬化斑块及hs-CRP水平,安全性高.

Effects of Ezetimibe Combined with Rosuvastatin on Blood Fat,Carotid Atherosclerotic Plaques and hs-CRP of Patient with Coronary Heart Disease

Objective To investigate effects of Ezetimibe combined with Rosuvastatin on blood fat, carotid ath-erosclerotic plaques and high sensitive C-reactive protein ( hs-CRP) of patient with coronary heart disease. Methods A total of 102 patients with coronary heart disease admitted during January 2015 and August 2015 were divided into observa-tion group and control group ( n=51 for each group) according to different treatment methods. Control group was treated with simple Rosuvastatin, while observation group was treated with Ezetimibe combined with Rosuvastatin. Changes of blood fat, carotid atherosclerotic plaques and hs-CRP before and after treatment and incidence rate of adverse reaction were compared in two groups. Results After treatment for 1 and 3 monthes, total cholesterol ( TC) and low density lipo-protein cholesterol ( LDL-C) levels in two groups and triglyceride ( TG) level in observation group were significantly lower than those before treatment, and the levels in observation group were significantly lower than those in control group ( P<0. 05). After treatment, numbers of carotid atherosclerotic plaques and hs-CRP levels were significantly decreased com-pared with those before treatment in two groups, and the values in observation group were significantly lower than those in control group (P<0. 05). There was no significantly difference in incidence rate of adverse reaction between two groups P>0. 05). Conclusion Ezetimibe combined with Rosuvastatin in treatment of patient with coronary heart disease can effectively improve blood fat, carotid atherosclerotic plaques and hs-CRP levels with high safety.